Дикин Д.С., Мазин А.В. Анемия Фанкони: на перекрестке репарации ДНК (обзор). Биохимия. 2011;76(1):46–61.
Dikin D.S., Mazin A.V. Fanconi Anemia: at the Crossroads of DNA Repair (review). Biokhimiya. 2011;76(1):46–61. (In Russian).
Aksu T., Gümrük F., Bayhan T. et al. Central nervous system lesions in Fanconi anemia: experience from a research center for Fanconi anemia patients. Pediatr. Blood. Cancer. 2020;67(12):e28722.
DOI: 10.1002/pbc.28722.
Alter B., Giri N., Hogan W. et al. Diagnosis of Fanconi Anemia in an asymptomatic adult with mosaicism and a molecular explanation. Blood. 2009;114:4213–4213.
DOI: 10.1182/blood.V114.22.4213.4213.
Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am. Soc. Hematol. Educ. Program. Published online 2007:29–39.
DOI: 10.1182/asheducation-2007.1.29.
Alter B.P., Giri N. Thinking of VACTERL-H? Rule out Fanconi Anemia according to PHENOS. Am. J. Med. Genet. A. 2016;170(6):1520–1524.
DOI: 10.1002/ajmg.a.37637.
Alter B.P., Giri N., Savage S.A. et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol. 2010;150(2):179–188.
DOI: 10.1111/j.1365-2141.2010.08212.x.
Alter B.P., Joenje H., Oostra A.B. et al. Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch. Otolaryngol. Head Neck Surg. 2005;131(7):635–639.
DOI: 10.1001/archotol.131.7.635.
Alter B.P., Rosenberg P.S. VACTERL-H Association and Fanconi Anemia. Mol. Syndromol. 2013;4(1-2):87–93.
DOI: 10.1159/000346035.
Alter B.P., Rosenberg P.S., Brody L.C. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J. Med. Genet. 2007;44(1):1–9.
DOI: 10.1136/jmg.2006.043257.
Altintas B., Giri N., McReynolds L.J. et al. Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. Haematologica. 2023;108(1):69–82.
DOI: 10.3324/haematol.2021.279981.
Auerbach A.D. Diagnosis of Fanconi Anemia by Diepoxybutane Analysis. Curr. Protoc. Hum. Genet. 2015;85:8.7.1-8.7.17.
DOI: 10.1002/0471142905.hg0807s85.
Ayas M., Saber W., Davies S.M. et al. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J. Clin. Oncol. 2013;31(13):1669–1676.
DOI: 10.1200/JCO.2012.45.9719.
Bierings M., Bonfim C., Peffault De Latour R. et al. Transplant results in adults with Fanconi anaemia. Br. J. Haematol. 2018;180(1):100–109.
DOI: 10.1111/bjh.15006.
Brosh R.M., Bellani M., Liu Y. et al. Fanconi Anemia: A DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging. Ageing Res Rev. 2017;33:67–75.
DOI: 10.1016/j.arr.2016.05.005.
Calado R.T., Clé D.V. Treatment of inherited bone marrow failure syndromes beyond transplantation. Hematology Am. Soc. Hematol. Educ. Program. 2017;2017(1):96–101.
DOI: 10.1182/asheducation-2017.1.96.
Castella M., Pujol R., Callén E. et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood. 2011;117(14):3759–3769.
DOI: 10.1182/blood-2010-08-299917.
Denny M., Haug S.J., Cunningham E.T. et al. Fanconi anemia presenting as bilateral diffuse retinal occlusive vasculopathy. Retin. Cases Brief. Rep. 2016;10(2):171–174.
DOI: 10.1097/ICB.0000000000000219.
Dufour C., Pierri F. Modern management of Fanconi anemia. Hematology Am. Soc. Hematol. Educ. Program. 2022;2022(1):649–657.
DOI: 10.1182/hematology.2022000393.
Easton D.F., Pharoah P.D.P., Antoniou A.C. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 2015;372(23):2243–2257.
DOI: 10.1056/NEJMsr1501341.
Elgohary M.A., Lim K.S., Siriwardena D. et al. Increased crystalline lens thickness and phacomorphic glaucoma in patients with Fanconi anemia. J. Cataract. Refract. Surg. 2006;32(10):1771–1774.
DOI: 10.1016/j.jcrs.2006.04.036.
Esmer C., Sánchez S., Ramos S. et al. DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am. J. Med. Genet. A. 2004;124A(1):35–39.
DOI: 10.1002/ajmg.a.20327.
Faivre L., Guardiola P., Lewis C. et al. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood. 2000;96(13):4064–4070.
Faivre L., Portnoï M.F., Pals G. et al. Should chromosome breakage studies be performed in patients with VACTERL association? Am. J. Med. Genet. A. 2005;137(1):55–58.
DOI: 10.1002/ajmg.a.30853.
Fiesco-Roa M.O., Giri N., McReynolds L.J. et al. Genotype-phenotype associations in Fanconi anemia: A literature review. Blood. Rev. 2019;37:100589.
DOI: 10.1016/j.blre.2019.100589.
Gadalla S.M., Cawthon R., Giri N. et al. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany NY). 2010;2(11):867–874.
DOI: 10.18632/aging.100235.
Giampietro P.F., Verlander P.C., Davis J.G. et al. Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am. J. Med. Genet. 1997;68(1):58–61.
Giri N., Batista D.L., Alter B.P. et al. Endocrine abnormalities in patients with Fanconi anemia. J. Clin. Endocrinol. Metab. 2007;92(7):2624–2631.
DOI: 10.1210/jc.2007-0135.
Hanenberg H., Andreassen P.R. PALB2 (partner and localizer of BRCA2). Atlas Genet. Cytogenet. Oncol. Haematol. 2018;22(12):484–490.
DOI: 10.4267/2042/69016.
Herman T.E., Siegel M.J. Fanconi’s anemia, type A presenting as VACTERL association with atresia right external auditory canal. J. Perinatol. 2010;30(1):73–76.
DOI: 10.1038/jp.2009.105.
Herman T.E., Siegel M.J. VACTERL-H syndrome. J. Perinatol. 2002;22(6):496–498.
DOI: 10.1038/sj.jp.7210765.
Huck K., Hanenberg H., Gudowius S. et al. Delayed diagnosis and complications of Fanconi anaemia at advanced age-a paradigm. Br. J. Haematol. 2006;133(2):188–197.
DOI: 10.1111/j.1365-2141.2006.05998.x.
Kanemoto N., Fukushima T., Imoto N. et al. Sporadic neonatal Fanconi’s anemia with VACTERL association. Pediatr. Int. 2010;52(1):141–142.
DOI: 10.1111/j.1442-200X.2009.02945.x.
Kee Y., D’Andrea A.D. Molecular pathogenesis and clinical management of Fanconi anemia. J. Clin. Invest. 2012;122(11):3799–3806.
DOI: 10.1172/JCI58321.
Kimble D.C., Lach F.P., Gregg S.Q. et al. A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families. Hum. Mutat. 2018;39(2):237–254.
DOI: 10.1002/humu.23366.
Kutler D.I., Auerbach A.D. Fanconi anemia in Ashkenazi Jews. Fam. Cancer. 2004;3(3-4):241–248.
DOI: 10.1007/s10689-004-9565-8.
Kutler D.I., Singh B., Satagopan J. et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249–1256.
DOI: 10.1182/blood-2002-07-2170.
Kwee M.L., van der Kleij J.M., van Essen A.J. et al. An atypical case of Fanconi anemia in elderly sibs. Am. J. Med. Genet. 1997;68(3):362–366.
Lach F.P., Singh S., Rickman K.A. et al. Esophageal cancer as initial presentation of Fanconi anemia in patients with a hypomorphic FANCA variant. Cold. Spring. Harb. Mol. Case Stud. 2020;6(6):a005595.
DOI: 10.1101/mcs.a005595.
Levitus M., Waisfisz Q., Godthelp B.C. et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 2005;37(9):934–935.
DOI: 10.1038/ng1625.
Lichtman M., Spivak J., Boxer L. et al. Commentary on and reprint of Fanconi G, Familiäre infantile perniziosaartige Anämie (perniziöses Blutbild und Konstitution), in Jahrbuch für Kinderheilkunde. 1927;117:257–280. In: Elsevier; 2000:127–166.
DOI: 10.1016/B978-012448510-5/50106-0. (In Deutsch).
MacMillan M.L., DeFor T.E., Young J.A.H. et al. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 2015;125(24):3798–3804.
DOI: 10.1182/blood-2015-02-626002.
Mikat B., Roll C., Schindler D. et al. X-linked recessive VACTERL-H due to a mutation in FANCB in a preterm boy. Clin. Dysmorphol. 2016;25(2):73–76.
DOI: 10.1097/MCD.0000000000000111.
Moreno O.M., Sánchez A.I., Herreño A. et al. Phenotypic Characteristics and Copy Number Variants in a Cohort of Colombian Patients with VACTERL Association. Mol. Syndromol. 2020;11(5-6):271–283.
DOI: 10.1159/000510910.
Moyer C.L., Ivanovich J., Gillespie J.L. et al. Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. Cancer Res. 2020;80(4):857–867.
DOI: 10.1158/0008-5472.CAN-19-1991.
Peake J.D., Noguchi E. Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair. Hum. Genet. 2022;141(12):1811–1836.
DOI: 10.1007/s00439-022-02462-9.
Perel Y., Butenandt O., Carrere A. et al. Oesophageal atresia, VACTERL association: Fanconi’s anaemia related spectrum of anomalies. Arch. Dis. Child. 1998;78(4):375–376.
DOI: 10.1136/adc.78.4.375.
Petryk A., Kanakatti Shankar R., Giri N. et al. Endocrine disorders in Fanconi anemia: recommendations for screening and treatment. J. Clin. Endocrinol. Metab. 2015;100(3):803–811.
DOI: 10.1210/jc.2014-4357.
Pinto F.O., Leblanc T., Chamousset D. et al. Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica. 2009;94(4):487–495.
DOI: 10.3324/haematol.13592.
Rosenberg P.S., Greene M.H., Alter B.P. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–826.
DOI: 10.1182/blood-2002-05-1498.
Rosenberg P.S., Tamary H., Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J. Med. Genet. A. 2011;155A(8):1877–1883.
DOI: 10.1002/ajmg.a.34087.
Savage S.A., Walsh M. Myelodysplastic syndrome, acute myeloid leukemia, and cancer surveillance in Fanconi Anemia. Hematol. Oncol. Clin. North Am. 2018;32(4):657–668.
DOI: 10.1016/j.hoc.2018.04.002.
Seal S., Thompson D., Renwick A. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 2006;38(11):1239–1241.
DOI: 10.1038/ng1902.
Sevilla J., Navarro S., Rio P. et al. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Mol. Ther. Methods Clin. Dev. 2021;22:66–75.
DOI: 10.1016/j.omtm.2021.06.001.
Shimamura A., Alter B.P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood. Rev. 2010;24(3):101–122.
DOI: 10.1016/j.blre.2010.03.002.
Solomon B.D., Bear K.A., Kimonis V. et al. Clinical geneticists’ views of VACTERL/VATER association. Am. J. Med. Genet. A. 2012;158A(12):3087–3100.
DOI: 10.1002/ajmg.a.35638.
Stivaros S.M., Alston R., Wright N.B. et al. Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging. Br. J. Radiol. 2015;88(1056):20150088.
DOI: 10.1259/bjr.20150088.
Tischkowitz M., Dokal I. Fanconi anaemia and leukaemia — clinical and molecular aspects. Br. J. Haematol. 2004;126(2):176–191.
DOI: 10.1111/j.1365-2141.2004.05023.x.
Triemstra J., Pham A., Rhodes L. et al. A Review of Fanconi Anemia for the Practicing Pediatrician. Pediatr. Ann. 2015;44(10):444–445, 448, 450passim.
DOI: 10.3928/00904481-20151012-11.
Vanuytsel K., Cai Q., Nair N. et al. FANCA knockout in human embryonic stem cells causes a severe growth disadvantage. Stem. Cell Res. 2014;13(2):240–250.
DOI: 10.1016/j.scr.2014.07.005.
Velleuer E., Dietrich R. Fanconi anemia: young patients at high risk for squamous cell carcinoma. Mol. Cell. Pediatr. 2014;1(1):9.
DOI: 10.1186/s40348-014-0009-8.
Verlander P.C., Lin J.D., Udono M.U. et al. Mutation analysis of the Fanconi anemia gene FACC. Am. J. Hum. Genet. 1994;54(4):595–601.
Weber-Lassalle N., Hauke J., Ramser J. et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast. Cancer Res. 2018;20(1):7.
DOI: 10.1186/s13058-018-0935-9.
Wijker M., Morgan N.V., Herterich S. et al. Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene. Eur. J. Hum. Genet. 1999;7(1):52–59.
DOI: 10.1038/sj.ejhg.5200248.
Woodward E.R., Meyer S. Fanconi Anaemia, Childhood cancer and the BRCA genes. Genes (Basel). 2021;12(10):1520.
DOI: 10.3390/genes12101520.
Yamashita T., Wu N., Kupfer G. et al. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. Blood. 1996;87(10):4424–4432.